

Human ICOS-L/B7-H2



www.mesoscale.com

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com


Company Address

MESO SCALE DISCOVERY®
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (hu)
Singleplex	K151AHJK-1/-2/-4	U-PLEX Human ICOS-L/B7-H2 Assay with SECTOR™ plates
	K151AHJK-21/-22/-24	U-PLEX Human ICOS-L/B7-H2 Assay with QuickPlex® plates
	K251AHJK-2/-4	U-PLEX Human ICOS-L/B7-H2 Assay with 384-well plates
Antibody Set	B21AHJ-2/-3	U-PLEX Human ICOS-L/B7-H2 Antibody Set
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com .	

The U-PLEX® platform was designed to provide ultimate flexibility for the detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX Human ICOS-L/B7-H2 Assay tested on U-PLEX plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
ICOS-L/B7-H2	0.98	0.58–2.8

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	2,000	4.1	6.7
Mid	441	2.1	6.1
Low	89	2.4	8.9

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only.
Not for use in diagnostic procedures.

MSD® U-PLEX Human ICOS-L/B7-H2

Tested Samples

Sample Type	Serum (N = 9)	EDTA Plasma (N = 9)	Citrate Plasma (N = 9)	Normal Lysate (N = 5)	Tumor Lysate (N = 5)
Median (pg/mL)	139,000	138,000	111,000	701	703
Range (pg/mL)	94,300–174,000	95,500–174,000	78,500–145,000	337–1,170	349–2,360
% Detected	100	100	100	100	100

Normal serum and plasma samples were tested without dilution before the assay. Lysates were tested at a protein concentration of 0.5 mg/mL.

Parallelism

Serum			EDTA Plasma		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
50	96	90–102	50	92	87–98
200	103	99–110	200	104	94–110
400	105	100–109	400	111	96–122

Samples were tested at different dilutions. One hundred-fold diluted samples were tested to determine the expected concentration of the analyte.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Spike Recovery

Spike Level	Serum		EDTA Plasma	
	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	99	57–118	98	65–117
Mid	113	88–127	103	100–109
Low	101	92–110	94	79–103

Samples were diluted 100-fold prior to addition of spike. The expected concentration of the analyte in spiked samples was calculated by addition of the Calibrator spike concentration to the unspiked sample concentration.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Specificity

To assess specificity, the ICOS-L/B7-H2 Antibody Set was tested individually against a larger panel of analytes for nonspecific binding (APRIL/TNFSF13, BAFF-R/TNFSF13C, BCMA/TNFSF17, β NGF, BDNF, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), C-Peptide, CTACK, CTLA-4, Desghrelin, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Galectin-9, Ghrelin (Ser3-octanoylated), GIP (1–42), GIP (3–42), GPCR/TNFSF18, GPCR/TNFSF18, GLP-1 (7–36), GLP-1 (9–36), Glucagon, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO- α HAVCR2/TIM-3, HVEM/TNFSF14, I-309, ICOS, ICOSL/B7-H2, IFN- α , IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-2, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- λ , IL-2R α , IL-3, IL-31, IL-33, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, Insulin, IP-10, I-TAC, LAG-3, Leptin, LH, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α , MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, OX40/TNFSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, PP, Proinsulin, P-Selectin, PYY (3–36), RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 α TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RII, TNF- α , TNF- β , TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1 and YKL-40). Nonspecific binding was less than 2.0%.

$$\% \text{ Nonspecificity} = (\text{nonspecific signal} / \text{specific signal}) \times 100$$

The ICOS-L/B7-H2 analyte interacted with the Nectin-4 detection antibody (4.4%). We do not recommend multiplexing the ICOS-L/B7-H2 assay with the Nectin-4 assay.

Diluent Compatibility

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: ICOS-L/B7-H2 is included in Calibrator 29. The human ICOS-L/B7-H2 Calibrator is a full-length recombinant protein expressed in a human cell line.

Antibodies: The U-PLEX Human ICOS-L/B7-H2 Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

Note: MSD recommends that samples be diluted 100-fold prior to analysis in this assay.

